Group items tagged

Amid the rapid rise in semaglutide usage, a study has suggested a potential risk of a rare eye condition associated with the weight loss drug. Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is available under the brand name Ozempic (by Novo Nordisk) in a lower-dose form for managing type 2 diabetes mellitus (T2DM), and as Wegovy (also by Novo Nordisk) in a higher-dose form for weight management in patients with high body mass indexes. Anecdotal evidence has indicated that semaglutide might be linked to nonarteritic anterior ischemic optic neuropathy (NAION). To investigate this potential connection, researchers in the United States analysed data over a six-year period from nearly 17,000 neuro-ophthalmology patients at Massachusetts Eye and Ear Hospital in Boston, Massachusetts, all of whom had no prior history of NAION.

In his first speech as Secretary of State for Health and Social Care, Wes Streeting MP acknowledged that the NHS is in crisis while outlining his mission to save the health service. Streeting described the current state of the NHS as "broken," noting its failure to meet the needs of both patients and dedicated healthcare professionals. "When we said during the election campaign, that the NHS was going through the biggest crisis in its history, we meant it. "When we said that patients are being failed on a daily basis, it wasn't political rhetoric, but the daily reality faced by millions," he said on Friday (5 July). The new health secretary remarked that previous governments had been unwilling to admit these simple facts.

GlaxoSmithKline (GSK) says initial tests of the antibody-based Covid-19 therapy it is developing with US partner Vir suggest the drug is effective against the Omicron variant. A GSK statement on Thursday (December 2) said that lab tests and a study on hamsters have demonstrated the sotrovimab antibody cocktail to work against viruses that were bio-engineered to carry a number of hallmark mutations of the new variant. The tests are continuing to confirm the results against all of the Omicron mutations, with an update expected by the end of the year, it added. The antibody is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron has been found to have an unusually high amount of mutations on that protein. "Sotrovimab was deliberately designed with a mutating virus in mind," said Vir chief executive George Scangos, adding that the drug was targeting a region of the spike protein that was highly unlikely to mutate.

The Medicines & Healthcare products Regulatory Agency has initiated a recall of three batches of Quantum Pharmaceutical's Diltiazem HCl 2% Cream, which is an unlicensed medicine. MHRA issued a precautionary recall of the cream due to a change in the product's appearance that affected its thickness. Pharmacists are instructed to halt supply, quarantine remaining stock, and contact Quantum Pharmaceutical to return affected batches M1402497, M1402574, and M1402680. Patients using this product may encounter application issues with the cream due to its consistency. However, MHRA said that this has not impacted the product's effectiveness or posed any risk to patient safety. The MHRA also reported that medac GmbH (t/a medac Pharma LLP) is conducting a recall of two batches of Sodiofolin 50 mg/ml solution for injection/infusion (400mg/8ml vial) with batch numbers G220393B and G220393C. This class 2 medicines recall is a result of particles detected during long-term stability tests.

With 118 new cases confirmed by the UK Health Security Agency (UKHSA), the total number of measles cases reported in England since 1 October 2023 has gone up to 465. According to the latest data published by the agency, West Midlands continues to see a disproportionately high rate of infections, with a sharp rise in case numbers over the last six weeks, mainly driven by cases in Birmingham. In England, there were 17 laboratory-confirmed measles cases in October, 42 in November, 161 in December, 240 in January 2024. Five more cases were confirmed last week, according to the measles statistics updated by UKHSA on 8 February. More than 70 per cent (329 of 465) of total confirmed cases were reported from the West Midlands, 13 per cent (62 of 465) from London, seven per cent (32 of 465) in Yorkshire and The Humber, and the remaining cases from other regions of England.

The National Health Service will begin its autumn Covid vaccine program next week, a month earlier than planned in response to the spread of a new variant dubbed Pirola. Covid vaccines will be administered to care home residents and housebound individuals from Monday onwards, while over-65s and other vulnerable groups will receive their appointments the week after. On Aug. 30, NHS England shifted the autumn vaccination drive to start on September 11 in response to the new Covid-19 variant, BA.2.86, detected on August 18. The primary groups can book through a national system upon receiving an invitation from the NHS. Some people may get an earlier call from their GP, and a few have already scheduled Covid vaccinations alongside their flu jabs. The NHS will begin inviting other eligible groups from Sept. 18. However, it is important to note that not everyone will receive a call at the same time. These groups will include individuals aged 65 and over, those aged six months to 64 years in a clinical risk category, frontline health and social care workers, and individuals aged 12 to 64 who are carers or household contacts of those with immunosuppression.

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

In response to stakeholder feedback, the General Pharmaceutical Council (GPhC) is developing a streamlined, single route to registration that will replace the current multiple-pathway system for overseas pharmacists wishing to practice in Great Britain. This revised approach will include updated standards for the education and training of internationally qualified pharmacists, with all applicants still required to pass a registration assessment. The GPhC's Council intends to streamline the registration pathway, reducing the two-year process to one-year process. This new pathway will encompass both university study and in-practice training. Historically, pharmacists qualified within the European Economic Area (EEA) or European Free Trade Association (EFTA) have been eligible for qualification recognition in Great Britain. While this recognition has been extended until September 2028, the future requirement for EEA-qualified pharmacists to undergo the new registration route remains contingent on forthcoming government decisions. Initially, the GPhC had explored the development of three distinct registration routes for internationally-qualified pharmacists, "however decided to change this proposed approach after considering feedback from stakeholders."

During a debate on Thursday (5) members of the House of Lords voiced unanimous concern over the alarming rise in retail crime and its impact on businesses, workers, and communities. Lord Hannett of Everton (Labour), former General Secretary of the Union of Shop, Distributive and Allied Workers (USDAW), initiated the debate, citing alarming statistics from the Office for National Statistics (ONS). The ONS figures showed that nearly 470,000 shoplifting offences were recorded across England and Wales in the year leading up to October 2024- a 29 per cent increase and the highest figure since records started in March 2003. Lord Hannett highlighted widespread underreporting of retail crime, noting "many retail workers do not report incidents because they simply do not believe that anything will happen when they do." He pointed to a British Retail Consortium survey revealing over 1,300 incidents of violence and abuse against retail workers daily in 2022-2023, with only a third reported to the police and fewer than 8 per cent leading to prosecutions.

Professor Anthony Harnden has officially commenced his role as chair of the Medicines and Healthcare products Regulatory Agency (MHRA). During his first 100 days, Professor Harnden plans to engage extensively with MHRA staff and partner organisations to gain a strong understanding of "how to drive forward the strategic direction of the MHRA to maintain the UK as a global centre of excellence in life sciences, in the best interests of patients and the public." The new MHRA chair has highlighted three primary areas of focus: Protect patient safety through robust safety surveillance systems Embrace risk-proportionate regulation Foster an inclusive workplace where people flourish. With a 40-year career in the NHS, including 33 years as a general practitioner in Wheatley, Oxfordshire, Professor Harnden brings a wealth of experience to the role. He is a professor of primary care at the University of Oxford. Until December 2024, he was also a registrant council member of the General Medical Council and chair of the Remuneration Committee.

The Medicines and Health products Regulatory Agency (MHRA) on Thursday issued a class 4 medicines defect information notice for Cozaar 100mg film-coated tablets due to an error in the Patient Information Leaflets (PILs) reported by the company. Cozaar is used to treat high blood pressure (hypertension) as well as to slow the progression of kidney disease in people who have type 2 diabetes mellitus. Quadrant Pharmaceuticals Ltd has informed the UK regulatory authority that the PILs that have been packed in certain batches of the products do not have the most up to date safety information. 'Grapefruit juice should be avoided while taking Cozaar'- This information is missing in Section 2 'What you need to know before you take Cozaar', sub section 'Cozaar with food and drink', the company clarified.

With scarlet fever currently circulating in England, the UK Health Security Agency (UKSHA) has urged parents to remain vigilant for potential symptoms in children. Also known as scarlatina, it is an infectious disease triggered by group A strep bacteria that can lead to symptoms such as fever, a sandpapery rash, sore throat and swollen tonsils. The latest data published by the UKHSA showed that a total of 19,528 cases of scarlet fever were reported in the 2023/24 season, of which 12,176 cases occurring between 1 January and 24 March 2024. While the number of cases recorded this year is lower than those recorded during the same period in 2023, which totaled 15,933 cases, it exceeds the average for the previous five years. "Scarlet fever is a common childhood illness, although it can affect anyone of any age," said Dr Theresa Lamagni at UKHSA. Parents are advised to contact their GP practice or NHS111 when their GP is unavailable, if they suspect they or their child are experiencing symptoms of scarlet fever.